US7456222B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti tubercular drug: compositions and methods
Assignee: Sequella Inc
•
Filing: 2005-07-01
•
Granted: 2008-11-25
•
Expires: 2025-07-01
Abstract
Abstract Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.
Inventors
- 👤 Marina Nikolaevna Protopopova
- 👤 Richard Edward Lee
- 👤 Richard Allan Slayden
- 👤 Clifton E. Barry, III
- 👤 Elena Bogatcheva
- 👤 Leo Einck
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 19:13
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/132; A61K31/135; A61K31/137; A61P; A61P31/00; A61P31/04; A61P31/06; A61P31/08; A61P31/10; A61P31/12; A61P33/00; C; C07; C07C; C07C211/00; C07C211/01; C07C215/00; C07C215/02; C07C215/04; C07C215/06; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
126 words
A method of treating disease caused by an a mycobacterial agent comprising administering an effective amount of a substituted ethylene diamine compound of the formula wherein R 4 is selected from H, alkyl, aryl, heteroatom substituted alkyl and aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, or heteroaryl; or wherein R 1 is selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, silyl, and NR 2 R 3 is derived from a cyclic secondary amine; including straight or branched chain derivative thereof, cyclic derivative thereof, substituted derivative thereof, functionalized derivative thereof, salts thereof, isomers thereof, or a combination thereof; optionally in a pharmaceutical carrier.
Claim 2
Independent Claim
126 words
A method of treating disease caused by an a mycobacterial agent comprising administering an effective amount of a substituted ethylene diamine compound of the formula wherein R 4 is selected from H, alkyl, aryl, heteroatom substituted alkyl and aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, or heteroaryl; or wherein R 1 is selected from H, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, silyl, and NR 2 R 3 is derived from a cyclic secondary amine; including straight or branched chain derivative thereof, cyclic derivative thereof, substituted derivative thereof, functionalized derivative thereof, salts thereof, isomers thereof, or a combination thereof; optionally in a pharmaceutical carrier.
Claim 3
Dependent Claim
23 words
The method of claim 1 , wherein NHR 1 or NR 2 R 3 of the substituted ethylene diamine has the chemical structure
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein the substituted ethylene diamine compound is selected from
Claim 5
Dependent Claim
23 words
The method of claim 1 , wherein NHR 1 or NR 2 R 3 of the substituted ethylene diamine has the chemical structure
Claim 6
Dependent Claim
15 words
The method of claim 4 , wherein the substituted ethylene diamine compound is selected from
Claim 7
Dependent Claim
23 words
The method of claim 1 , wherein NHR 1 or NR 2 R 3 of the substituted ethylene diamine has the chemical structure
Claim 8
Dependent Claim
15 words
The method of claim 6 , wherein the substituted ethylene diamine compound is selected from
Claim 9
Dependent Claim
23 words
The method of claim 1 , wherein NHR 1 or NR 2 R 3 of the substituted ethylene diamine has the chemical structure
Claim 10
Dependent Claim
15 words
The method of claim 8 , wherein the substituted ethylene diamine compound is selected from
Claim 11
Dependent Claim
15 words
The method of claim 1 , wherein the substituted ethylene diamine compound is selected from
Claim 12
Dependent Claim
43 words
The method of claim 1 , wherein the mycobacterial agent comprises M. tuberculosis, M. avium - intracellulare, M. kansarii, M. fortuitum, M. chelonae, M. leprae, M. africanum, M. microti, M. avium paratuberculosis, M. intracellulare, M. scrofulaceum, M. xenopi, M. marinum, or M. ulcerans.
Claim 13
Dependent Claim
12 words
The method of claim 1 , wherein the infectious disease comprises tuberculosis.
Claim 14
Independent Claim
76 words
A method of treating disease caused by an mycobacterial agent comprising administering an effective amount of a symmetrical substituted ethylene diamine compound of the formula wherein R 4 is selected from H, alkyl, aryl, heteroatom substituted alkyl and aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, aryl, alkenyl, alkynyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, heteroaryl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino.
Claim 15
Independent Claim
76 words
A method of treating disease caused by an mycobacterial agent comprising administering an effective amount of a symmetrical substituted ethylene diamine compound of the formula wherein R 4 is selected from H, alkyl, aryl, heteroatom substituted alkyl and aryl, alkenyl, alkynyl, aralkyl, aralkynyl, cycloalkyl, cycloalkenyl; and wherein R 1 , R 2 and R 3 are independently selected from H, aryl, alkenyl, alkynyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkenyl, heteroaryl, halide, alkoxy, aryloxy, alkylthio, arylthio, silyl, siloxy, amino.
Claim 16
Dependent Claim
41 words
The method of claim 1 , wherein NHR 1 of the substituted ethylene diamine is selected from 1-adamantanemethylamine, 2,2,-diphenylethylamine, 3,3-diphenylpropylamine, 2-amino-1-butanol, cis-(−)myrtanylamine, cyclooctylamine, 2-adamantamine, (+)-bomylamine, cyclohexyethylamine, undecylamine, geranylamine, (+)-isopinocampheylamine, (−)-isopinocampheylamine, or a combination thereof, or substituted derivatives thereof, or stereoisomers thereof.
Claim 17
Dependent Claim
43 words
The method of claim 1 , wherein NR 2 R 3 of the substituted ethylene diamine is selected from 1-adamantanemethylamine, 2,2,-diphenylethylamine, 3,3-diphenylpropylamine, 2-amino-1-butanol, cis-(−)myrtanylamine, cyclooctylamine, 2-adamantamine, (+)-bomylamine, cyclohexyethylamine, undecylamine, geranylamine, (+)-isopinocampheylamine, (−)-isopinocampheylamine, or a combination thereof, or substituted derivatives thereof, or stereoisomers thereof.
Claim 18
Dependent Claim
30 words
The method of claim 1 , wherein R 1 , R 2 , and R 3 are selected from isopinocamphenyl; bomyl; norbomyl; adamantanetetyl; cis-(−)myrtanyl; adamantyl; noradamantyl; 6-azabicyclo[3 .2.1]octane; or exo-norbomane.
Claim 19
Dependent Claim
16 words
The method of claim 1 , wherein the infectious agent comprises a drug resistant mycobacterial strain.
Claim 20
Dependent Claim
28 words
The method of claim 1 , wherein administering the effective amount of substituted ethylene diamine compound comprises topical, oral, peritoneal, implantable, subcutaneous, intramuscular, intraocular, intraarterial or intravenous administration.
Claim 21
Dependent Claim
20 words
The method of claim 1 , wherein the substituted ethylene diamine compound is administered as a solid, liquid or aerosol.
Claim 22
Dependent Claim
17 words
The method of claim 19 , wherein the solid comprises pills, creams, soaps or implantable dosage units.
Claim 23
Dependent Claim
19 words
The method of claim 19 , wherein the liquid comprises liquid formulations adapted for injection, topical or ocular administration.
Claim 24
Dependent Claim
13 words
The method of claim 19 , wherein the aerosol comprises an inhaler formulation.
Claim 25
Dependent Claim
17 words
The method of claim 19 , wherein the solid, liquid or aerosol comprises a sustained release matrix.
Claim 26
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 100 to 0.1 mg per kg of body weight.
Claim 27
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 50 to 0.2 mg per kg of body weight.
Claim 28
Dependent Claim
26 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 25 to 0.5 mg per kg of body weight.
Claim 29
Dependent Claim
21 words
The method of claim 1 , wherein the effective amount of substituted ethylene diamine compound comprises from 1 to 1000 mg.
References Cited (Backward Citations)
US2623878A
Cited
GB729332A
Cited
GB961317A
Cited
US3176040A
Cited
US3553257A
Cited
USRE29588E
Cited
US3579587A
Cited
FR2007524A1
Cited
US3579586A
Cited
GB1234349A
Cited
US3718655A
Cited
US3769347A
Cited
US3878201A
Cited
US3847991A
Cited
US3829493A
Cited
USRE29358E
Cited
US3855300A
Cited
US3979457A
Cited
US3953513A
Cited
US3931152A
Cited
US3944616A
Cited
US3931157A
Cited
US4006234A
Cited
US4150030A
Cited
US3944619A
Cited
US3944608A
Cited
US3944618A
Cited
US3944617A
Cited
US4262122A
Cited
US4450274A
Cited
US5104875A
Cited
US5985935A
Cited
US5439891A
Cited
US5922282A
Cited
WO1999051213A2
Cited
RU2168986C1
Cited
US20030236225A1
Cited
US20040033986A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2011-11-25 | 2012-05-26 | 2012-11-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2015-11-25 | 2016-05-26 | 2016-11-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2019-11-25 | 2020-05-26 | 2020-11-25 | $7700.00 | Window Closed / Lapsed |